Evidence map›Paper›PMID 42609802›Full record

ArticleAdvances in pharmacological and pharmaceutical sciences2026

The Ethanol-Insoluble Low-Molecular-Weight Fraction LEP-4 Derived From

Masanobu Tsubaki, Taira Matsuo, Rie Komori, Tomoya Takeda, Noriaki Nagai, Toshio Morikawa, Shozo Nishida

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in pharmacological and pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Ethanol-Insoluble Low-Molecular-Weight Fraction LEP-4 Derived FromAdvances in pharmacological and pharmaceutical sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masanobu TsubakiLaboratory of Pharmacotherapy, Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Sanuki 760-8542, Kagawa, Japan, bunri-u.ac.jp.ORCID https://orcid.org/0000-0003-3129-2678
Taira MatsuoLaboratory of Pharmacotherapy, Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Sanuki 760-8542, Kagawa, Japan, bunri-u.ac.jp.
Rie KomoriLaboratory of Pharmacotherapy, Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Sanuki 760-8542, Kagawa, Japan, bunri-u.ac.jp.
Tomoya TakedaFaculty of Pharmacy, Osaka Ohtani University, Tondabayashishi 584-8540, Osaka, Japan, osaka-ohtani.ac.jp.
Noriaki NagaiDepartment of Pharmacy, Kindai University, Higashiosaka 577-8502, Osaka, Japan, kindai.ac.jp.
Toshio MorikawaPharmaceutical Research and Technology Institute, Kindai University, Higashiosaka 577-8502, Osaka, Japan, kindai.ac.jp.ORCID https://orcid.org/0000-0003-2794-5365
Shozo NishidaDepartment of Pharmacy, Kindai University, Higashiosaka 577-8502, Osaka, Japan, kindai.ac.jp.ORCID https://orcid.org/0000-0002-3408-0462

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse event caused by drugs such as bortezomib, vincristine, paclitaxel, and oxaliplatin (L-OHP). This condition can lead to the discontinuation of anticancer drug administration and a diminished quality of life, posing a significant clinical problem. However, the only currently recognized effective treatment is duloxetine, and new therapeutic options are urgently required.

Indexed as

allodyniaethanol-insoluble fractionLentinula edodes mycelianeuropathyoxaliplatin

Identifiers

PMID42609802
PMCPMC13479112

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.